Abstract:BACKGROUND & AIMS: Esophagectomy is the standard treatment for early-stage esophageal squamous cell carcinoma (EESCC), but patients who undergo this procedure have high morbidity and mortality. Endoscopic submucosal dissection (ESD) is a less-invasive procedure for treatment of EESCC, but is considered risky because this tumor frequently metastasizes to the lymph nodes. We aimed to directly compare outcomes of patients with EESCC treated with ESD vs esophagectomy. METHODS: We performed a retrospective cohort study of patients with T1a-m2/m3, or T1b EESCCs who underwent ESD (n = 322) or esophagectomy (n = 274) from October 1, 2011 through September 31, 2016 at Zhongshan Hospital in Shanghai, China. The primary outcome was all-cause mortality at the end of follow up (minimum of 6 months). Secondary outcomes included operation time, hospital stay, cost, perioperative mortalities/severe non-fatal adverse events, requirement for adjuvant therapies, and disease-specific mortality and cancer recurrence or metastasis at the end of the follow up period. RESULTS: Patients who underwent ESD were older (mean 63.5 years vs 62.3 years for patients receiving esophagectomy; P = .006) and a greater proportion was male (80.1% vs 70.4%; P = .006) and had a T1a tumor (74.5% vs 27%; P = .001). A lower proportion of patients who underwent ESD had perioperative mortality (0.3% vs 1.5% of patients receiving esophagectomy; P = .186) and non-fatal severe adverse events (15.2% vs 27.7%; P = .001)-specifically lower proportions of esophageal fistula (0.3% of patients receiving ESD vs 16.4% for patients receiving esophagectomy; P = .001) and pulmonary complications (0.3% vs 3.6%; P = .004). After a median follow-up time of 21 months (range, 6-73 months), there were no significant differences between treatments in all-cause mortality (7.4% for ESD vs 10.9%; P = .209) or rate of cancer recurrence or metastasis (9.1% for ESD vs 8.9%; P = .948). Disease-specific mortality was lower among patients who received ESD (3.4%) vs patients who patients who received esophagectomy (7.4%) (P = .049). In Cox regression analysis, depth of tumor invasion was the only factor associated with all-cause mortality (T1a-m3 or deeper vs T1a-m2: hazard ration, 3.54; P = .04). CONCLUSION: In a retrospective study of patients with T1am2/m3 or T1b EESCCs treated with ESD (n = 322) or esophagectomy (n = 274), we found lower proportions of patients receiving ESD to have perioperative adverse events or disease specific mortality after a median follow up time of 21 months. We found no difference in overall survival or cancer recurrence or metastasis in patients with T1a or T1b ESCCs treated with ESD vs esophagectomy.

Does delayed esophagectomy after endoscopic resection affect outcomes in patients with stage T1 esophageal cancer? A propensity score-based analysis

The Efficacy of Additional Surgical Resection after Endoscopic Resection in Pt1b Esophageal Squamous Cell Carcinoma: A Multi-Institutional Retrospective Study in China

Outcomes of Endoscopic Submucosal Dissection Vs Esophagectomy for T1 Esophageal Squamous Cell Carcinoma in a Real-World Cohort

Long-term Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Esophagectomy Following Neoadjuvant Chemotherapy: a Cohort Study

Oesophagectomy following noncurative endoscopic resection for oesophageal carcinoma: does interval matter?

Comparative Analysis of Esophagectomy after Endoscopic Resection in Early Stage Esophageal Cancer

Therapeutic Strategies Following Endoscopic Submucosal Dissection for T1a-MM/T1b-SM1 Esophageal Squamous Cell Carcinoma: Comparisons of Long-Term Outcomes with Propensity Score-Matched Analysis

Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Propensity-matched study on locally advanced esophageal cancer: surgery versus post-operative radiotherapy

Early esophageal cancer or precancerous lesions treated by endoscopic resection: a single-center retrospective study of 368 cases

Long-term outcomes of additional surgery after endoscopic resection versus primary surgery for T1 colorectal cancer

Postoperative Adjuvant Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Cancer: A Propensity Score-Matched Analysis (APEC Study 1).

Postoperative Adjuvant Chemotherapy or Chemoradiation Versus Surgery Alone for Thoracic Pathological Node Positive Esophageal Cancer: A Propensity Score-Matched Analysis (APEC Study 2)

The Influence of Different Treatment Strategies on the Long-Term Prognosis of T1 Stage Esophageal Cancer Patients

Clinical outcomes of primary esophagectomy and secondary esophagectomy after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma: A propensity-score matched analysis.

Simultaneous endoscopic submucosal dissection for synchronous multiple early esophageal squamous cell carcinoma: a propensity score-matched analysis

Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis

Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study

Role of chemotherapy after curative esophagectomy in squamous cell carcinoma of the thoracic esophagus: A propensity score‐matched analysis

Impact of treatment delays on future survival outcomes in non-surgical patients with esophageal cancer in Shandong Province, China

A retrospective study of endoscopic resection for 368 patients with early esophageal squamous cell carcinoma or precancerous lesions